Investing.com -- U.S. health regulators will require drugmakers including Novo Nordisk A/S (NYSE:NVO) and Eli Lilly and Company (NYSE:LLY) to add safety warnings to their blockbuster weight-loss and diabetes treatments regarding a rare eye condition that can cause permanent vision loss. The Food and Drug Administration said Monday that all glucagon-like peptide-1 (GLP-1) receptor agonists must update their prescribing labels to reflect a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION.
The regulatory mandate follows a comprehensive agency evaluation that reviewed adverse event reports alongside a meta-analysis of 126 clinical trials encompassing more than 134,000 patients. That analysis identified an incidence rate of 6.4 NAION cases per 100,000 patient-years among GLP-1 users, compared with 3.8 cases per 100,000 patient-years in comparator groups receiving placebos or alternative glucose-lowering drugs.
While the FDA noted that available animal data did not identify an underlying biological mechanism, real-world observational data and commercial network findings underscored an elevated risk profile when compared against certain older diabetes therapies. In a retrospective Sentinel network cohort study of adults with type 2 diabetes, GLP-1 treatments exhibited a 43% higher risk of NAION relative to DPP-4 inhibitors, though no statistically significant divergence emerged when measured against SGLT-2 inhibitors.
The labeling update arrives against a backdrop of escalating legal and clinical scrutiny for manufacturers of semaglutide and tirzepatide franchises. Dozens of patients have initiated litigation against Novo Nordisk and Eli Lilly alleging drug-induced vision impairment, while four patients in Denmark were awarded compensation last year for developing the optic nerve condition.
Drugmakers maintain that available studies do not prove a direct causal link between the therapies and NAION, and companies retain the formal ability to challenge regulatory labeling updates before the FDA issues a final determination. For investors, the agency's requirement introduces a fresh headline headwind for the high-margin obesity category, which continues to navigate heavy clinical scrutiny as patient exposure expands globally.
Original Article
FDA requires vision-loss warning on Novo Nordisk and Eli Lilly GLP-1 drugs
Anthropic targets next-week IPO despite AI market volatility, WSJ reports
Nvidia intervention preceded transfer of chip probe to Justice Department
